Androgens And Parkinson's Disease: The Role In Humans And In Experiment

September 2022 in “ Problems of Endocrinology ”

Aida U. Hamadyanova, К.О. Кузнецов, E. I. Gaifullina, D. A. Kalandin, R. R. Khamidullina, I. F. Khalitova, R. M. Faizov, N. O. Kamaletdinova, B. F. Aslanova, A. G. Nakieva, L. E. Burangulova, G. O. Gaisina

androgens 5α-reductase inhibitors dutasteride dopamine neurons sex hormones Avodart

Studysummary This review discusses sex differences in Parkinson's disease and highlights that while men are more frequently affected, androgen-modulating treatments have not yet proven effective for PD, though 5α-reductase inhibitors show potential for further study.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on probl-endojournals.ru →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

36 citations , November 2020 in “Journal of The European Academy of Dermatology and Venereology”

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

research Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective

34 citations , September 2020 in “BMC Endocrine Disorders”

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

Physiopathological Role of the Enzymatic Complex 5α-Reductase and 3α/β-Hydroxysteroid Oxidoreductase in the Generation of Progesterone and Testosterone Neuroactive Metabolites

research Physiopathological Role of the Enzymatic Complex 5α-Reductase and 3α/β-Hydroxysteroid Oxidoreductase in the Generation of Progesterone and Testosterone Neuroactive Metabolites

18 citations , March 2020 in “Frontiers in Neuroendocrinology”

This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.

5alpha-Reductase Inhibitors Dampen L-DOPA-Induced Dyskinesia via Normalization of Dopamine D1-Receptor Signaling Pathway and D1-D3 Receptor Interaction

research 5alpha-Reductase Inhibitors Dampen L-DOPA-Induced Dyskinesia via Normalization of Dopamine D1-Receptor Signaling Pathway and D1-D3 Receptor Interaction

26 citations , September 2018 in “Neurobiology of Disease”

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

research Effect of the 5α-Reductase Enzyme Inhibitor Dutasteride in the Brain of Intact and Parkinsonian Mice

16 citations , October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology”

This study found that dutasteride may offer neuroprotection in early-stage Parkinson's disease by preventing loss of striatal dopamine and altering steroid levels in MPTP-lesioned mice.

research The 5-Alpha Reductase Inhibitor Finasteride Reduces Dyskinesia in a Rat Model of Parkinson’s Disease

15 citations , January 2017 in “Experimental Neurology”

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

research The Neurosteroidogenic Enzyme 5α-Reductase Modulates the Role of D1 Dopamine Receptors in Rat Sensorimotor Gating

49 citations , September 2015 in “Psychoneuroendocrinology”

This study suggests that the 5α-reductase inhibitor finasteride modulates sensorimotor gating in rats by affecting D1 and D3 receptors, but not D2 receptors, with varying effects based on genetic strain.

research The 5α-Reductase Inhibitor Dutasteride but Not Finasteride Protects Dopamine Neurons in the MPTP Mouse Model of Parkinson’s Disease

27 citations , May 2015 in “Neuropharmacology”

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

Finasteride Attenuates Pathological Gambling in Patients With Parkinson's Disease